PRESS RELEASE published on 04/15/2024 at 14:01, 2 years 6 months ago Original-Research: Apontis Pharma AG (von Montega AG): Kaufen Montega AG stuft Apontis Pharma AG hoch und aktualisiert das Kursziel auf 16,50 EUR aufgrund neuer Vertriebsstrategie und Kooperation mit Novartis. Analyst Tim Kruse empfiehlt Kauf Montega AG APONTIS PHARMA AG Kursziel 16,50 EUR Vertriebsstrategie Kooperation Novartis
BRIEF published on 04/05/2024 at 10:22, 2 years 6 months ago APONTIS PHARMA Secures Five-Year Distribution and Marketing Deal with Novartis for Asthma Medications Pharmaceutical Industry Financial Forecast APONTIS PHARMA Asthma Medications Novartis
BRIEF published on 04/05/2024 at 10:22, 2 years 6 months ago APONTIS PHARMA conclut un accord de distribution et de commercialisation de cinq ans avec Novartis pour des médicaments contre l'asthme Prévisions Financières Industrie Pharmaceutique PHARMA APONTIS Médicaments Contre L'asthme Novartis
PRESS RELEASE published on 04/05/2024 at 10:17, 2 years 6 months ago APONTIS PHARMA enters five-year distribution and marketing agreement with Novartis for two asthma medications and raises forecast APONTIS PHARMA partners with Novartis for asthma medications distribution and marketing, raising forecast for 2024 financial year Distribution Agreement APONTIS PHARMA Asthma Medications Novartis Forecast Increase
BRIEF published on 04/05/2024 at 10:15, 2 years 6 months ago APONTIS PHARMA AG Enhances Forecast Following Agreement with Novartis APONTIS PHARMA AG Financial Growth Forecast Upgrade Novartis Agreement Asthma Medications
BRIEF published on 04/05/2024 at 10:15, 2 years 6 months ago APONTIS PHARMA AG améliore ses prévisions suite à un accord avec Novartis Croissance Financière APONTIS PHARMA AG Mise À Niveau Des Prévisions Accord Novartis Médicaments Contre L'asthme
PRESS RELEASE published on 04/05/2024 at 10:10, 2 years 6 months ago EQS-Adhoc: APONTIS PHARMA AG raises forecast after entering five-year distribution and marketing agreement with Novartis for two asthma medications APONTIS PHARMA AG raises forecast following agreement with Novartis for asthma medications Forecast Raise Financial Outlook APONTIS PHARMA AG Novartis Agreement Asthma Medications
BRIEF published on 03/28/2024 at 07:35, 2 years 6 months ago APONTIS PHARMA Anticipates Profitable Growth in 2024 After Restructuring APONTIS PHARMA Single Pill Combinations Financial Results 2023 Profitable Growth 2024 Restructuring Program
BRIEF published on 03/28/2024 at 07:35, 2 years 6 months ago APONTIS PHARMA prévoit une croissance rentable en 2024 après sa restructuration Résultats Financiers 2023 PHARMA APONTIS Croissance Rentable 2024 Combinaisons De Pilules Uniques Programme De Restructuration
PRESS RELEASE published on 03/28/2024 at 07:30, 2 years 6 months ago APONTIS PHARMA expects profitable growth again in 2024 APONTIS PHARMA expects profitable growth in 2024 with sales forecasted to rise to EUR 41.7 million and positive EBITDA of EUR 1.8 million. Performance and efficiency improvements drive future growth EBITDA Profitable Growth APONTIS PHARMA Sales Forecast Efficiency Improvements
Published on 10/16/2026 at 08:00, 58 minutes ago Caledonia Mining Corporation Plc: Notification of Relevant Change to Significant Shareholder
Published on 10/16/2026 at 05:55, 3 hours 3 minutes ago Collective Metals Announces Private Placement of Hard Dollar and Flow-Through Units
Published on 10/16/2026 at 02:10, 6 hours 48 minutes ago Nova Scotia Silver Explorer TruSilver Metals Corp. Anticipates TSXV Trading Under "TAG" on October 27
Published on 10/16/2026 at 01:45, 7 hours 13 minutes ago Faraday Copper Closes the Acquisition of the San Manuel Project in Arizona and Mobilizes Drill Rigs
Published on 10/16/2026 at 01:30, 7 hours 28 minutes ago LNG Energy Group Announces Closing of Second Tranche of Private Placement
Published on 10/16/2026 at 07:30, 1 hour 28 minutes ago Steyr Motors and drone specialist Avilus are cooperating on the power supply for the Grille unmanned aircraft system
Published on 10/16/2026 at 07:00, 1 hour 58 minutes ago PolyPeptide Group: Definitive interim result of the public tender offer of Samsung Biologics Co., Ltd.
Published on 10/15/2026 at 22:30, 10 hours 28 minutes ago Porsche Mission S: the essence of the sports car reinterpreted
Published on 10/16/2026 at 07:30, 1 hour 28 minutes ago Chiffre d'affaires du troisième trimestre 2026
Published on 10/15/2026 at 18:50, 14 hours 8 minutes ago September & first 9 months of 2026 traffic figures - Revision of Traffic assumptions for 2026
Published on 10/15/2026 at 18:50, 14 hours 8 minutes ago Trafic du mois de septembre et des 9 premiers mois de l'année 2026 - Révision des hypothèses de trafic pour l'année 2026
Published on 10/15/2026 at 18:16, 14 hours 42 minutes ago Déclaration des droits de vote au 30 septembre 2026
